{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,23]],"date-time":"2026-10-23T19:14:26Z","timestamp":1792782866080,"version":"4.5.0"},"reference-count":20,"publisher":"Springer Science and Business Media LLC","issue":"5","license":[{"start":{"date-parts":[[2025,2,21]],"date-time":"2025-02-21T00:00:00Z","timestamp":1740096000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2025,2,21]],"date-time":"2025-02-21T00:00:00Z","timestamp":1740096000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"funder":[{"name":"National Key Clinic Specialized Subject Project of China"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Eur J Clin Microbiol Infect Dis"],"published-print":{"date-parts":[[2025,5]]},"DOI":"10.1007\/s10096-025-05077-w","type":"journal-article","created":{"date-parts":[[2025,2,21]],"date-time":"2025-02-21T04:50:50Z","timestamp":1740113450000},"page":"1245-1250","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":5,"title":["Successful treatment of carbapenem-resistant Acinetobacter baumannii meningitis and purulent ventriculitis using cefiderocol combination therapy: a case report and literature review"],"prefix":"10.1007","volume":"44","author":[{"given":"Xuan","family":"Wang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qihui","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Biwu","family":"Wu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Huaiyin","family":"Zhao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jin","family":"Hu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ning","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,2,21]]},"reference":[{"issue":"1","key":"5077_CR1","doi-asserted-by":"publisher","first-page":"112","DOI":"10.1016\/j.ijantimicag.2006.08.035","volume":"29","author":"G Metan","year":"2007","unstructured":"Metan G, Alp E, Aygen B, Sumerkan B (2007) Carbapenem-resistant Acinetobacter baumannii: an emerging threat for patients with post-neurosurgical meningitis. Int J Antimicrob Agents 29(1):112\u2013113. https:\/\/doi.org\/10.1016\/j.ijantimicag.2006.08.035","journal-title":"Int J Antimicrob Agents"},{"issue":"4","key":"5077_CR2","doi-asserted-by":"publisher","first-page":"908","DOI":"10.1093\/jac\/dkn018","volume":"61","author":"A Rodr\u00edguez Guardado","year":"2008","unstructured":"Rodr\u00edguez Guardado A, Blanco A, Asensi V, P\u00e9rez F, Rial JC, Pintado V, Bustillo E, Lantero M, Tenza E, Alvarez M, Maradona JA, Cart\u00f3n JA (2008) Multidrug-resistant Acinetobacter meningitis in neurosurgical patients with intraventricular catheters: assessment of different treatments. J Antimicrob Chemother 61(4):908\u2013913. https:\/\/doi.org\/10.1093\/jac\/dkn018","journal-title":"J Antimicrob Chemother"},{"issue":"3","key":"5077_CR3","doi-asserted-by":"publisher","first-page":"dlaa060","DOI":"10.1093\/jacamr\/dlaa060","volume":"2","author":"C Longshaw","year":"2020","unstructured":"Longshaw C, Manissero D, Tsuji M, Echols R, Yamano Y (2020) In vitro activity of the siderophore cephalosporin, cefiderocol, against molecularly characterized, carbapenem-non-susceptible gram-negative bacteria from Europe. JAC Antimicrob Resist 2(3):dlaa060. https:\/\/doi.org\/10.1093\/jacamr\/dlaa060","journal-title":"JAC Antimicrob Resist"},{"issue":"9","key":"5077_CR4","doi-asserted-by":"publisher","first-page":"e0264620","DOI":"10.1128\/aac.02646-20","volume":"65","author":"JC Abdul-Mutakabbir","year":"2021","unstructured":"Abdul-Mutakabbir JC, Nguyen L, Maassen PT, Stamper KC, Kebriaei R, Kaye KS, Castanheira M, Rybak MJ (2021) In Vitro Antibacterial Activity of Cefiderocol against Multidrug-Resistant Acinetobacter baumannii. Antimicrob Agents Chemother 65(9):e0264620. https:\/\/doi.org\/10.1128\/aac.02646-20","journal-title":"Antimicrob Agents Chemother"},{"key":"5077_CR5","doi-asserted-by":"publisher","unstructured":"Tamma PD, Heil EL, Justo JA, Mathers AJ, Satlin MJ, Bonomo RA (2024) Infectious Diseases Society of America 2024 Guidance on the treatment of antimicrobial-resistant gram-negative infections. https:\/\/doi.org\/10.1093\/cid\/ciae403. Clin Infect Dishttps:\/\/","DOI":"10.1093\/cid\/ciae403"},{"issue":"4","key":"5077_CR6","doi-asserted-by":"publisher","first-page":"245","DOI":"10.1016\/s1473-3099(09)70055-6","volume":"9","author":"BN Kim","year":"2009","unstructured":"Kim BN, Peleg AY, Lodise TP, Lipman J, Li J, Nation R, Paterson DL (2009) Management of meningitis due to antibiotic-resistant Acinetobacter species. Lancet Infect Dis 9(4):245\u2013255. https:\/\/doi.org\/10.1016\/s1473-3099(09)70055-6","journal-title":"Lancet Infect Dis"},{"issue":"4","key":"5077_CR7","doi-asserted-by":"publisher","first-page":"646","DOI":"10.1016\/j.ijantimicag.2017.12.002","volume":"51","author":"S Chusri","year":"2018","unstructured":"Chusri S, Sakarunchai I, Kositpantawong N, Panthuwong S, Santimaleeworagun W, Pattharachayakul S, Singkhamanan K, Doi Y (2018) Outcomes of adjunctive therapy with intrathecal or intraventricular administration of colistin for post-neurosurgical meningitis and ventriculitis due to carbapenem-resistant acinetobacter baumannii. Int J Antimicrob Agents 51(4):646\u2013650. https:\/\/doi.org\/10.1016\/j.ijantimicag.2017.12.002","journal-title":"Int J Antimicrob Agents"},{"key":"5077_CR8","doi-asserted-by":"publisher","first-page":"1381123","DOI":"10.3389\/fmed.2024.1381123","volume":"11","author":"JW Snowdin","year":"2024","unstructured":"Snowdin JW, Mercuro NJ, Madaio MP, Rawlings SA (2024) Case report: successful treatment of OXA-23 Acinetobacter baumannii neurosurgical infection and meningitis with sulbactam-durlobactam combination therapy. Front Med (Lausanne) 11:1381123. https:\/\/doi.org\/10.3389\/fmed.2024.1381123","journal-title":"Front Med (Lausanne)"},{"issue":"4","key":"5077_CR9","doi-asserted-by":"publisher","first-page":"819","DOI":"10.1093\/cid\/ciae210","volume":"79","author":"PD Tamma","year":"2024","unstructured":"Tamma PD, Immel S, Karaba SM, Soto CL, Conzemius R, Gisriel E, Tekle T, Stambaugh H, Johnson E, Tornheim JA, Simner PJ (2024) Successful treatment of Carbapenem-Resistant Acinetobacter baumannii Meningitis with Sulbactam-Durlobactam. Clin Infect Dis 79(4):819\u2013825. https:\/\/doi.org\/10.1093\/cid\/ciae210","journal-title":"Clin Infect Dis"},{"issue":"12","key":"5077_CR10","doi-asserted-by":"publisher","first-page":"1319","DOI":"10.1016\/s1473-3099(18)30554-1","volume":"18","author":"S Portsmouth","year":"2018","unstructured":"Portsmouth S, van Veenhuyzen D, Echols R, Machida M, Ferreira JCA, Ariyasu M, Tenke P, Nagata TD (2018) Cefiderocol versus imipenem-cilastatin for the treatment of complicated urinary tract infections caused by Gram-negative uropathogens: a phase 2, randomised, double-blind, non-inferiority trial. Lancet Infect Dis 18(12):1319\u20131328. https:\/\/doi.org\/10.1016\/s1473-3099(18)30554-1","journal-title":"Lancet Infect Dis"},{"issue":"2","key":"5077_CR11","doi-asserted-by":"publisher","first-page":"226","DOI":"10.1016\/s1473-3099(20)30796-9","volume":"21","author":"M Bassetti","year":"2021","unstructured":"Bassetti M, Echols R, Matsunaga Y, Ariyasu M, Doi Y, Ferrer R, Lodise TP, Naas T, Niki Y, Paterson DL, Portsmouth S, Torre-Cisneros J, Toyoizumi K, Wunderink RG, Nagata TD (2021) Efficacy and safety of cefiderocol or best available therapy for the treatment of serious infections caused by carbapenem-resistant Gram-negative bacteria (CREDIBLE-CR): a randomised, open-label, multicentre, pathogen-focused, descriptive, phase 3 trial. Lancet Infect Dis 21(2):226\u2013240. https:\/\/doi.org\/10.1016\/s1473-3099(20)30796-9","journal-title":"Lancet Infect Dis"},{"issue":"2","key":"5077_CR12","doi-asserted-by":"publisher","first-page":"213","DOI":"10.1016\/s1473-3099(20)30731-3","volume":"21","author":"RG Wunderink","year":"2021","unstructured":"Wunderink RG, Matsunaga Y, Ariyasu M, Clevenbergh P, Echols R, Kaye KS, Kollef M, Menon A, Pogue JM, Shorr AF, Timsit JF, Zeitlinger M, Nagata TD (2021) Cefiderocol versus high-dose, extended-infusion meropenem for the treatment of Gram-negative nosocomial pneumonia (APEKS-NP): a randomised, double-blind, phase 3, non-inferiority trial. Lancet Infect Dis 21(2):213\u2013225. https:\/\/doi.org\/10.1016\/s1473-3099(20)30731-3","journal-title":"Lancet Infect Dis"},{"issue":"1","key":"5077_CR13","doi-asserted-by":"publisher","first-page":"52","DOI":"10.1186\/s13613-023-01146-5","volume":"13","author":"P Viale","year":"2023","unstructured":"Viale P, Sandrock CE, Ramirez P, Rossolini GM, Lodise TP (2023) Treatment of critically ill patients with cefiderocol for infections caused by multidrug-resistant pathogens: review of the evidence. Ann Intensive Care 13(1):52. https:\/\/doi.org\/10.1186\/s13613-023-01146-5","journal-title":"Ann Intensive Care"},{"key":"5077_CR14","unstructured":"Takemura M, Kanazawa S, Kohira N, Aoe Y, Morimoto A, Horiuchi K, Inoue Y, Yamano Y 1106 Evaluation of penetration of Cefiderocol into Cerebrospinal Fluid using a rat meningitis model. (2328\u20138957 (Electronic))"},{"issue":"4","key":"5077_CR15","doi-asserted-by":"publisher","first-page":"dlab188","DOI":"10.1093\/jacamr\/dlab188","volume":"3","author":"M Meschiari","year":"2021","unstructured":"Meschiari M, Volpi S, Faltoni M, Dolci G, Orlando G, Franceschini E, Menozzi M, Sarti M, Del Fabro G, Fumarola B, Guarneri F, Lanza P, Lorenzotti S, Saccani B, Signorini L, Van Hauwermeiren E, Gatti M, Pea F, Castelli F, Mussini C (2021) Real-life experience with compassionate use of cefiderocol for difficult-to-treat resistant Pseudomonas aeruginosa (DTR-P) infections. JAC Antimicrob Resist 3(4):dlab188. https:\/\/doi.org\/10.1093\/jacamr\/dlab188","journal-title":"JAC Antimicrob Resist"},{"key":"5077_CR16","unstructured":"Stevenson DR, Cherian BP, Kinzig M, S\u00f6rgel F, Wareham DW P44 nosocomial neurosurgical meningitis due to XDR Pseudomonas aeruginosa: clinical experience with cefiderocol. LID - dlac 004.043. (2632\u2013\u20091823 (Electronic))"},{"issue":"6","key":"5077_CR17","doi-asserted-by":"publisher","first-page":"1787","DOI":"10.1093\/jac\/dkac066","volume":"77","author":"D Luque-Paz","year":"2022","unstructured":"Luque-Paz D, Bennis Y, Jaubert P, Dub\u00e9e V, Wolff M, Mortaza S (2022) Cerebrospinal fluid concentrations of cefiderocol during the treatment of extensively drug-resistant Pseudomonas aeruginosa Ventriculitis. J Antimicrob Chemother 77(6):1787\u20131789. https:\/\/doi.org\/10.1093\/jac\/dkac066","journal-title":"J Antimicrob Chemother"},{"issue":"8","key":"5077_CR18","doi-asserted-by":"publisher","first-page":"ofac391","DOI":"10.1093\/ofid\/ofac391","volume":"9","author":"C Marcelo","year":"2022","unstructured":"Marcelo C, de Gea Grela A, Palazuelos MM, Veganzones J, Grandioso D, D\u00edaz-Poll\u00e1n B (2022) Clinical cure of a difficult-to-treat resistant Pseudomonas aeruginosa Ventriculitis using cefiderocol: a Case Report and Literature Review. Open Forum Infect Dis 9(8):ofac391. https:\/\/doi.org\/10.1093\/ofid\/ofac391","journal-title":"Open Forum Infect Dis"},{"issue":"10","key":"5077_CR19","doi-asserted-by":"publisher","first-page":"2737","DOI":"10.1093\/jac\/dkac248","volume":"77","author":"WD Kufel","year":"2022","unstructured":"Kufel WD, Abouelhassan Y, Steele JM, Gutierrez RL, Perwez T, Bourdages G, Nicolau DP (2022) Plasma and cerebrospinal fluid concentrations of cefiderocol during successful treatment of carbapenem-resistant Acinetobacter baumannii meningitis. J Antimicrob Chemother 77(10):2737\u20132741. https:\/\/doi.org\/10.1093\/jac\/dkac248","journal-title":"J Antimicrob Chemother"},{"issue":"2","key":"5077_CR20","doi-asserted-by":"publisher","first-page":"178","DOI":"10.1016\/j.cmi.2023.08.029","volume":"30","author":"S Karakonstantis","year":"2024","unstructured":"Karakonstantis S, Rousaki M, Vassilopoulou L, Kritsotakis EI (2024) Global prevalence of cefiderocol non-susceptibility in Enterobacterales, Pseudomonas aeruginosa, Acinetobacter baumannii, and Stenotrophomonas maltophilia: a systematic review and meta-analysis. Clin Microbiol Infect 30(2):178\u2013188. https:\/\/doi.org\/10.1016\/j.cmi.2023.08.029","journal-title":"Clin Microbiol Infect"}],"container-title":["European Journal of Clinical Microbiology & Infectious Diseases"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10096-025-05077-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s10096-025-05077-w\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10096-025-05077-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,5,8]],"date-time":"2025-05-08T08:54:40Z","timestamp":1746694480000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s10096-025-05077-w"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,2,21]]},"references-count":20,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2025,5]]}},"alternative-id":["5077"],"URL":"https:\/\/doi.org\/10.1007\/s10096-025-05077-w","relation":{},"ISSN":["0934-9723","1435-4373"],"issn-type":[{"value":"0934-9723","type":"print"},{"value":"1435-4373","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,2,21]]},"assertion":[{"value":"10 November 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"14 February 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"21 February 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}